Targeted correction of the point mutations of beta-thalassemia and targeted mutagenesis of the nucleotide associated with HPFH by RNA/DNA oligonucleotides: potential for beta-thalassemia gene therapy.
An RNA/DNA chimeric oligonucleotide was found to be effective in the targeted correction of point mutations in Escherichia coli, plant, and mammalian genomes. This strategy, named chimeraplasty, has the potential for gene therapy of many genetic diseases caused by point mutations. beta-Thalassemia is a very common human genetic disease and in most cases it is caused by point mutations. To test whether the chimeraplasty can be used to correct the point mutations responsible for beta-thalassemia, we introduced one mutated beta-globin gene, betaE, into MEL cells and successfully corrected the point mutation of the betaE gene with the highest correction efficiency of 1.9%. Furthermore, a targeted -202 C-->G mutation of the Ggamma-globin gene, which is associated with the elevated Ggamma-globin gene expression in the adult stage, was introduced into HeLa and CMK cells by an RNA/DNA oligonucleotide. These results indicated that the chimeraplasty has potential for human beta-thalassemia gene therapy.
Li
Z H
ZH
National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Beijing, 100005, China.
Liu
D P
DP
Yin
W X
WX
Guo
Z C
ZC
Liang
C C
CC
D000818:Animals; D002460:Cell Line; D005319:Fetal Hemoglobin / Q000235:genetics*; D005786:Gene Expression Regulation; D018390:Gene Targeting; D015316:Genetic Therapy; D006801:Humans; D016296:Mutagenesis; D009841:Oligonucleotides; D017354:Point Mutation; D017086:beta-Thalassemia / Q000235:genetics* / Q000628:therapy
D009841:Oligonucleotides; D005319:Fetal Hemoglobin